EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
基本信息
- 批准号:10330633
- 负责人:
- 金额:$ 43.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-24 至 2022-01-23
- 项目状态:已结题
- 来源:
- 关键词:AgreementArbitrationBudgetsCohort StudiesCommunicationConflict (Psychology)DataData SetEnsureGoalsInstitutionIntellectual PropertyJointsKnowledgeMedicalMultiomic DataNatureOffice of Administrative ManagementOutcomePersonsPhasePilot ProjectsPlayPrincipal InvestigatorPublicationsResearchResourcesRoleSystemTechnology TransferTestingWorkbasecohortcomputerized toolsdesignknowledge graphmembermultiple omicsnovelproduct developmentprograms
项目摘要
1. Rationale for the joint effort as a multi-PI (MPI) team. At the core of the is pilot project is the
combination of two sets of resources and expertise that each of the two principal investigators
(PIs), Dr. Sergio Baranzini (UCSF) and Dr. Sui Huang (ISB) will contribute to develop, test and
deliver a computational tool (“Automatic Relay Agent”, ARA) as defined by the FOA of Biomedical
Translator program of NCATS as a milestone for the “First Segment” (January- March, 2020). The
ARA envisioned by this team is EVIDARA, a system that extracts knowledge from a knowledge
graph (KG) and evaluates it against multi-omics raw data of a large cohort for evidential support.
The evidenced-tested knowledge is then relaying it to the Biomedical Translator. The two
resources that will be combined to build EVIDARA are: (i) A novel knowledge graph, SPOKE and
(ii) a new genre of multi-omics data sets from scientific wellness studies. The two PIs will bring
these two resources and thus play complementary role: Dr. Sergio Baranzini, with his team at
UCSF, is the developer of SPOKE and Dr. Sui Huang provides subject matter expertise in multiomics
studies and has access to data from a cohort studied at ISB that he has been analyzing.
Dr. Baranzini will bring expertise in all computational aspects of SPOKE and its new applications
and Dr. Huang will also act as subject matter expert in multi-omics driven medical practice and
research to guide product development and testing.
2. Goal of project and continuation. The pilot project id defined by the common goal of
delivering the milestone product, EVIDARA as described in the proposal. If the pilot project is
successful and this team is selected to continue to the “Second Segment” (an up to five project)
the two PIs will work again as an MPI team and jointly design the expansion of the project into
this second phase and jointly prepare the new research plan to NCATS.
3. Management and coordination. Dr. Huang, is the contact-MPI and will coordinate the project
and directly communicate with Dr. Baranzini to ensure that both MPIs are kept informed about
the project’s technical progress and all administrative matters. Each MPI will assume fiscal and
administrative management of their own team, as reflected in the budget and consortium
subcontract. Dr. Huang will be responsible for communication with NCATS Program manager
team. The two MPIs and their team members and institutional collaborators agree to work jointly
as a group towards the milestone product. Should publications result, both will be co-senior
authors and their team members included as authors based on their contribution, following
common academic practice. If there are any conflicts in the course of the project, both PIs and
collaborators will meet in person and work in a spirit of cooperation to resolve any conflicts. Given
that Drs. Huang and Baranzini have interacted academically for almost two decades, share the
same scholarly perspective and the complementary and synergistic nature of their expertise that
is required for the project it is highly unlikely a neutral arbitration committee would be required to
resolve conflicts.
4. Intellectual Property. For intellectual property issue, the Technology Transfer Offices at each
of the PI’s institutions will be responsible for agreements relating to the research and the outcome
of the work.
1. 多 PI (MPI) 团队共同努力的理由 该试点项目的核心是:
两位主要研究者各自的两组资源和专业知识的结合
(PI)、Sergio Baranzini 博士 (UCSF) 和 Sui Huang 博士 (ISB) 将致力于开发、测试和
提供生物医学 FOA 定义的计算工具(“自动中继代理”,ARA)
NCATS 的翻译计划是“第一阶段”(2020 年 1 月至 3 月)的里程碑。
该团队设想的ARA是EVIDARA,一个从知识中提取知识的系统
图(KG)并根据大型队列的多组学原始数据对其进行评估以获得证据支持。
然后,经过验证的知识将被传递给生物医学翻译器。
构建 EVIDARA 的资源包括: (i) 新颖的知识图谱、SPOKE 和
(ii) 这两个 PI 将带来来自科学健康研究的新型多组学数据集。
这两种资源因此发挥互补作用:Sergio Baranzini 博士及其团队
UCSF 是 SPOKE 的开发者,Sui Huang 博士提供多组学方面的主题专业知识
研究并可以访问他一直在分析的 ISB 研究队列的数据。
Baranzini 博士将带来 SPOKE 及其新应用所有计算方面的专业知识
黄博士还将担任多组学驱动的医疗实践领域的主题专家
研究指导产品开发和测试。
2. 项目目标和延续性 由共同目标定义的试点项目 ID。
如果试点项目是,则交付里程碑产品 EVIDARA。
成功,该团队被选为继续“第二部分”(最多五个项目)
两位 PI 将再次作为 MPI 团队合作,共同设计该项目的扩展
第二阶段将与NCATS共同准备新的研究计划。
3. 管理和协调 黄博士是MPI的联系人,负责协调该项目。
并直接与 Baranzini 博士沟通,以确保两个 MPI 随时了解相关信息
每个 MPI 将承担项目的技术进展和所有行政事务。
自己团队的行政管理,如预算和财团所反映
黄博士将负责与NCATS项目经理的沟通。
两个 MPI 及其团队成员和机构合作者同意共同工作。
如果成果发表,两人将共同担任高级职务。
作者及其团队成员根据其贡献被列为作者,如下
如果项目过程中存在任何冲突,PI 和
合作者将亲自会面并本着合作精神解决任何冲突。
黄博士和 Baranzini 博士在学术上交往了近二十年,分享了
相同的学术观点以及他们的专业知识的互补和协同性质
该项目需要中立仲裁委员会的可能性很小
冲突解决。
4. 知识产权问题,请联系各技术转让办公室。
PI 的机构将负责与研究和结果相关的协议
的工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SERGIO E BARANZINI其他文献
SERGIO E BARANZINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SERGIO E BARANZINI', 18)}}的其他基金
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10057190 - 财政年份:2020
- 资助金额:
$ 43.73万 - 项目类别:
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10547256 - 财政年份:2020
- 资助金额:
$ 43.73万 - 项目类别:
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10706762 - 财政年份:2020
- 资助金额:
$ 43.73万 - 项目类别:
The genetic basis of progression in multiple sclerosis
多发性硬化症进展的遗传基础
- 批准号:
9737736 - 财政年份:2017
- 资助金额:
$ 43.73万 - 项目类别:
The genetic basis of progression in multiple sclerosis
多发性硬化症进展的遗传基础
- 批准号:
10084323 - 财政年份:2017
- 资助金额:
$ 43.73万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
9116321 - 财政年份:2014
- 资助金额:
$ 43.73万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
9330939 - 财政年份:2014
- 资助金额:
$ 43.73万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
8925166 - 财政年份:2014
- 资助金额:
$ 43.73万 - 项目类别:
相似国自然基金
苏云金杆菌噬菌体“仲裁”系统调控机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于排队论的仲裁网络结构性能分析与优化
- 批准号:
- 批准年份:2019
- 资助金额:60 万元
- 项目类别:面上项目
基于离线仲裁的量子令牌认证理论研究
- 批准号:61802118
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
不完全信息下最后要价仲裁对讨价还价的影响——基于理论和实验的分析
- 批准号:71401094
- 批准年份:2014
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
具有安全仲裁员的属性加密
- 批准号:61402136
- 批准年份:2014
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Core A - AdministrativeCore/Biocomputational Unit
核心 A - 管理核心/生物计算单元
- 批准号:
10397004 - 财政年份:2009
- 资助金额:
$ 43.73万 - 项目类别:
Core A - AdministrativeCore/Biocomputational Unit
核心 A - 管理核心/生物计算单元
- 批准号:
10602533 - 财政年份:2009
- 资助金额:
$ 43.73万 - 项目类别: